T. Casale

P229 Once-daily Tiotropium Respimat® As Add-on To At Least Medium- To High-dose Ics, With Or Without Laba, Improves Lung Function In Patients With Symptomatic Asthma, Independent Of Allergic Status

R. Dahl, J. Virchow, E. Pizzichini, 2014, Thorax.

Tiotropium respimat® add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of TH2 inflammatory status

R. Dahl, J. Virchow, E. Pizzichini, 2014, Allergy, Asthma & Clinical Immunology.

Safety and tolerability of omalizumab

S. Holgate, R. Buhl, J. Corren, 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

CYT003, a TLR9 agonist, in persistent allergic asthma – a randomized placebo‐controlled Phase 2b study

T. Casale, C. Vogelmeier, P. Saudan, 2015, Allergy.

The Asthma Control Questionnaire as a clinical trial endpoint: past experience and recommendations for future use

R. Dahl, I. Pavord, M. Wechsler, 2014, Allergy.